BioTime, Inc. (BTX) Stock: Here’s Why It’s Headed For The Top

0
72

BioTime, Inc. (BTX) is headed up in the market in today’s trading session. The stock, focused on the biotech sector, is presently priced at $1.18 after gaining 10.28% so far today. As it relates to biotechnology companies, there are a number of factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines associated with BTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-15-19 02:06AM Don’t Sell Forbuild SA (WSE:BTX) Before You Read This
May-14-19 11:23AM BioTime (BTX) Q1 2019 Earnings Call Transcript
May-13-19 09:13AM Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
May-10-19 01:48PM Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT
08:00AM BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

However, any time investors are making a decision to invest, prospective investors should look into much more than just news, this is especially the case in the generally speculative biotechnology industry. Here’s what’s going on with BioTime, Inc..

The Performance That BTX Investors Have Experienced

While a move up on a single session, like the gain that we’re seeing from BioTime, Inc. might lead to excitement in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It’s generally smart to dig into trends experienced by the stock beyond a single trading session. When it comes to BTX, here are the returns that investors have seen:

  • Weekly – Over the last five trading sessions, BTX has generated a change in value in the amount of -1.67%.
  • Monthly – The monthly returns from BioTime, Inc. comes to -9.23%.
  • Past 3 Months – Over the past quarter, the company has generated a return on investment that works out to 3.51%
  • Bi-Annually – In the last 6 months, investors have seen a change of -18.89% from the stock.
  • Year To Date – Since the the first trading session of this year BTX has produced a ROI of 29.24%.
  • Full Year – Lastly, in the past full year, we have seen a change of -28.89% from BTX. Over this period of time, the stock has traded at a high of -44.58% and a low price of 78.79%.

Ratios That Are Notable

Digging into various key ratios associated with a stock can give investors an understanding of how dangerous and/or rewarding a stock pick may be. Below are a few of the most important ratios to look at when looking at BTX.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this short ratio, the more investors believe that the value of the stock is headed for declines. In general, biotech stocks tend to come with a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, as it relates to BioTime, Inc., the stock’s short ratio comes to 13.67.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay for its debts when they come due using current assets or quick assets. Because many biotech several companies are heavily reliant on continued support from investors, the current and quick ratios can be damning. Nonetheless, quite a few better companies in the biotech space do have good quick and current ratios. In terms of BTX, the quick and current ratios work out to 5.30 and 5.30 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the price of shares. In this particular case, that ratio is 0.74.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is a very important ratio to look into. In this case, the cash to share value ratio is 0.21.

How Analysts Feel About BioTime, Inc.

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their opinions to validate your own opinions when it comes to making an investment decision in the biotechnology industry. Here are the most recent moves that we’ve seen from analysts with regard to BTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-21-19 Initiated H.C. Wainwright Buy $4
Jan-24-19 Initiated Maxim Group Buy $3
Dec-11-18 Initiated Oppenheimer Outperform $3.50
Feb-02-18 Initiated Lake Street Buy $8
Mar-31-17 Initiated Raymond James Outperform $6

Big Money And BioTime, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BTX, here’s what we’re seeing:

Institutions own 40.60% of the company. Institutional interest has moved by 6.12% over the past three months. When it comes to insiders, those who are close to the company currently own 3.90% percent of BTX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Investors and traders tend to have an interest in the counts of shares both outstanding and available. When it comes to BioTime, Inc., currently there are 145.95M with a float of 140.96M. These data mean that out of the total of 145.95M shares of BTX in existence today, 140.96M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BTX, the short percent of the float is 7.95%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.25. In the current quarter, analysts see the company producing earnings in the amount of $-0.05. Over the last 5 years, BTX has generated revenue in the amount of $2.40% with earnings coming in at 14.80%. On a quarter over quarter basis, earnings have seen movement of 38.50% and revenue has seen movement of -20.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can dig through social trends and other publicly available data, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here